SCHEMBL10249282

SCHEMBL10249282

Cc1cnc2c(c1)nc(-c1ccncc1SCC#N)n2C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.36
ALOX15 P16050 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
PDE10A Q9Y233 5/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
MAPK1 P28482 2/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.34
AKT1 P31749 2/20 0.33
AKT2 P31751 2/20 0.33
ALDH1A1 P00352 1/20 0.32
POLB P06746 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
BRD4 O60885 1/20 0.31
RAB9A P51151 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249155 0.89 HTT (0.37) L3MBTL1PDE10ASMN1; SMN2LMNAAKT1
SCHEMBL10249048 0.89 CA12 (0.36) CA12CA1CA2CA9CA14
SCHEMBL10284948 0.87 POLB (0.45) TSHRL3MBTL1CA12CA1CA2
SCHEMBL10248971 0.86 PDE10A (0.36) PDE10ASMN1; SMN2HPGDLMNAAKT1
SCHEMBL10249014 0.84 PDE10A (0.35) TSHRPDE10ASMN1; SMN2HPGDLMNA
SCHEMBL10252611 0.83 PDE10A (0.35) PDE10ASMN1; SMN2AKT1AKT2POLB
SCHEMBL10249293 0.83 AKT1 (0.36) PDE10ASMN1; SMN2AKT1AKT2POLB
SCHEMBL10252628 0.83 PDE10A (0.35) TSHRL3MBTL1PDE10ASMN1; SMN2MAPK1
SCHEMBL10249343 0.83 TSHR (0.42) TSHRALOX15L3MBTL1CA12CA1
SCHEMBL10249007 0.83 POLB (0.36) PDE10ASMN1; SMN2AKT1AKT2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 TSHR 396/4885ALOX15 2102/4885L3MBTL1 13/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 TSHR 396/4885ALOX15 2102/4885L3MBTL1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.